{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:17:58Z","timestamp":1793459878323,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T00:00:00Z","timestamp":1481068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ymgme.2016.12.001","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T11:16:42Z","timestamp":1481023002000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry"],"prefix":"10.1016","volume":"120","author":[{"given":"Amal","family":"El-Beshlawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szymanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Vellodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-741X","authenticated-orcid":false,"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin H.","family":"Kolodny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod K.","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.12.001_bb0005","series-title":"OMMBID: The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher disease","author":"Grabowski","year":"2013"},{"issue":"53","key":"10.1016\/j.ymgme.2016.12.001_bb0010","doi-asserted-by":"crossref","first-page":"41216","DOI":"10.1074\/jbc.X110.197954","article-title":"Benefits from unearthing \u201ca biochemical Rosetta Stone\u201d","volume":"285","author":"Brady","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0005-2744(68)90251-9","article-title":"The lysosomal localization of sphingolipid hydrolases","volume":"159","author":"Weinreb","year":"1968","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.3021","article-title":"The cellular pathology of lysosomal diseases","volume":"226","author":"Cox","year":"2012","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/hmg\/dds471","article-title":"Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds","volume":"22","author":"Tiscornia","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2016.12.001_bb0030","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/ajh.24063","article-title":"Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher Registry","volume":"90","author":"Grabowski","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2016.12.001_bb0035","first-page":"72","article-title":"Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history","volume":"12","author":"Baris","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10245330500067181","article-title":"Survey of hematological aspects of Gaucher disease","volume":"10","author":"Zimran","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.ymgme.2016.12.001_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","author":"Biegstraaten","year":"2010","journal-title":"Brain"},{"issue":"23\u201324","key":"10.1016\/j.ymgme.2016.12.001_bb0050","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10354-010-0850-x","article-title":"Neuropathic Gaucher disease","volume":"160","author":"Pastores","year":"2010","journal-title":"Wien. Med. Wochenschr."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2016.12.001_bb0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10545-010-9093-7","article-title":"The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations","volume":"33","author":"Poupetova","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"18","key":"10.1016\/j.ymgme.2016.12.001_bb0065","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymgme.2016.12.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2009.05.001","article-title":"Clinical and genetic study of Japanese patients with type 3 Gaucher disease","author":"Tajima","year":"2009","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bcmd.2010.07.010","article-title":"Clinical and genetic characteristics of Korean patients with Gaucher disease","volume":"46","author":"Jeong","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0080","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12519-011-0309-1","article-title":"Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes","volume":"7","author":"El-Morsy","year":"2011","journal-title":"World J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bcmd.2006.11.003","article-title":"Gaucher disease among Chinese patients: review on genotype\/phenotype correlation from 29 patients and identification of novel and rare alleles","volume":"38","author":"Choy","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0090","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000055","article-title":"Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt","volume":"2","author":"Abdelwahab","year":"2016","journal-title":"Neurol. Genet."},{"issue":"21","key":"10.1016\/j.ymgme.2016.12.001_bb0095","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","article-title":"Individualization of long-term enzyme replacement therapy for Gaucher disease","volume":"7","author":"Andersson","year":"2005","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(98)90023-6","article-title":"Enzyme therapy for Gaucher disease: the first 5years","volume":"12","author":"Grabowski","year":"1998","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"75","author":"Sims","year":"2008","journal-title":"Clin. Genet."},{"issue":"11","key":"10.1016\/j.ymgme.2016.12.001_bb0125","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/14656566.9.11.1987","article-title":"Imiglucerase and its use for the treatment of Gaucher's disease","volume":"9","author":"Weinreb","year":"2008","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2016.12.001_bb0145","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/ajh.24056","article-title":"Long-term treatment outcomes in Gaucher disease","volume":"90","author":"Charrow","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"9985","key":"10.1016\/j.ymgme.2016.12.001_bb0150","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ymgme.2016.12.001_bb0155","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0160","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.ymgme.2014.12.179","article-title":"ENGAGE: a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: results after 18months [abstract]","volume":"114","author":"Mistry","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0165","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ymgme.2014.12.058","article-title":"ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results [abstract]","volume":"114","author":"Cox","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0170","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1750-1172-7-102","article-title":"Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study","volume":"7","author":"Cox","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"8","key":"10.1016\/j.ymgme.2016.12.001_bb0180","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2014.07.022","article-title":"Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients","volume":"113","author":"Sechi","year":"2014","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2016.12.001_bb0190","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4318\/tjg.2011.0244","article-title":"Pediatric Gaucher experience in South Marmara region of Turkey","volume":"22","author":"Erdemir","year":"2011","journal-title":"Turk. J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.ymgme.2016.12.001_bb0195","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13312-011-0128-4","article-title":"Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India","volume":"48","author":"Nagral","year":"2011","journal-title":"Indian Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2007-979754","article-title":"Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease","volume":"26","author":"Erikson","year":"1995","journal-title":"Neuropediatrics"},{"issue":"9","key":"10.1016\/j.ymgme.2016.12.001_bb0205","first-page":"653","article-title":"A retrospective study on enzyme replacement therapy in patients with Gaucher disease","volume":"44","author":"Duan","year":"2006","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1445-5994.2004.00765.x","article-title":"Enzyme replacement therapy for Gaucher disease in Australia","volume":"35","author":"Goldblatt","year":"2005","journal-title":"Intern. Med. J."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0215","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ana.410420412","article-title":"Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease","volume":"42","author":"Schiffmann","year":"1997","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0220","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1067\/mpd.2001.112171","article-title":"The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease","volume":"138","author":"Altarescu","year":"2001","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.braindev.2010.02.005","article-title":"A French experience of type 3 Gaucher disease: phenotypic diversity and neurological outcome of 10 patients","volume":"33","author":"Kraoua","year":"2011","journal-title":"Brain Dev."},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0230","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.1993.tb03224.x","article-title":"Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease","volume":"85","author":"Zimran","year":"1993","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bcmd.2014.05.007","article-title":"Outcome of early-treated type III Gaucher disease patients","volume":"53","author":"Lee","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2016.12.001_bb0240","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-009-9009-6","article-title":"Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry","author":"Tylki-Szymanska","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2016.12.001_bb0245","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/ajh.24054","article-title":"The history and accomplishments of the ICGG Gaucher registry","volume":"90","author":"Weinreb","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"20","key":"10.1016\/j.ymgme.2016.12.001_bb0250","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"A. World Medical","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ymgme.2016.12.001_bb0255","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ymgme.2016.12.001_bb0260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1750-1172-9-45","article-title":"Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes","volume":"9","author":"Orenstein","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7863\/jum.1997.16.3.209","article-title":"Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements","volume":"16","author":"Elstein","year":"1997","journal-title":"J. Ultrasound Med."},{"key":"10.1016\/j.ymgme.2016.12.001_bb0270","series-title":"Clinical Growth Charts","author":"Center for Disease Control and Prevention","year":"2001"},{"issue":"6","key":"10.1016\/j.ymgme.2016.12.001_bb0275","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0280","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0888-7543(89)90319-4","article-title":"The human glucocerebrosidase gene and pseudogene: structure and evolution","volume":"4","author":"Horowitz","year":"1989","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0285","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1172\/JCI114415","article-title":"A glucocerebrosidase fusion gene in Gaucher disease. Implications for the molecular anatomy, pathogenesis, and diagnosis of this disorder","volume":"85","author":"Zimran","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"4 Suppl. 5","key":"10.1016\/j.ymgme.2016.12.001_bb0290","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"issue":"6","key":"10.1016\/j.ymgme.2016.12.001_bb0295","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10545-010-9175-6","article-title":"Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy","volume":"33","author":"Stein","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.12.001_bb0300","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2012.09175.x","article-title":"Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4\u20135years","author":"Hollak","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9610(91)90363-I","article-title":"A 27-year experience with splenectomy for Gaucher's disease","volume":"161","author":"Fleshner","year":"1991","journal-title":"Am. J. Surg."},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0315","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","article-title":"Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease","volume":"39","author":"Nilsson","year":"1982","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2016.12.001_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1651-2227.1986.tb14936.x","article-title":"Gaucher disease\u2013Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment","volume":"326","author":"Erikson","year":"1986","journal-title":"Acta Paediatr. Scand. Suppl."},{"issue":"8981","key":"10.1016\/j.ymgme.2016.12.001_bb0325","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(95)91688-1","article-title":"Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype","volume":"346","author":"Abrahamov","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0330","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bcmd.2012.09.008","article-title":"Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy","volume":"50","author":"Elstein","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2016.12.001_bb0335","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1034\/j.1399-0004.2001.590511.x","article-title":"Severe valvular and aortic arch calcification in a patient with Gaucher's disease homozygous for the D409H mutation","volume":"59","author":"George","year":"2001","journal-title":"Clin. Genet."},{"issue":"9","key":"10.1016\/j.ymgme.2016.12.001_bb0340","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jmg.32.9.740","article-title":"Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation","volume":"32","author":"Chabas","year":"1995","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0345","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/jmg.34.2.175","article-title":"D409H\/D409H genotype in Gaucher-like disease","volume":"34","author":"Uyama","year":"1997","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2016.12.001_bb0350","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1212\/WNL.54.1.261","article-title":"Gaucher disease with oculomotor apraxia and cardiovascular calcification (Gaucher type IIIC)","volume":"54","author":"Bohlega","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ymgme.2016.12.001_bb0355","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12098-015-2025-7","article-title":"Gaucher's disease with cardiac valve calcification and Stenosis: a rare presentation due to homozygous p.D409H mutation in a north Indian family","volume":"83","author":"Rastogi","year":"2016","journal-title":"Indian J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2016.12.001_bb0360","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/0974-2069.43883","article-title":"Gaucher's disease type III C: unusual cause of intracardiac calcification","volume":"1","author":"Shah","year":"2008","journal-title":"Ann. Pediatr. Cardiol."},{"issue":"6","key":"10.1016\/j.ymgme.2016.12.001_bb0365","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2016.12.001_bb0370","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1006\/bcmd.2000.0317","article-title":"A new gene-pseudogene fusion allele due to a recombination in intron 2 of the glucocerebrosidase gene causes Gaucher disease","volume":"26","author":"Cormand","year":"2000","journal-title":"Blood Cells Mol. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2016.12.001_bb0375","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1136\/jmg.2004.028019","article-title":"Divergent phenotypes in Gaucher disease implicate the role of modifiers","volume":"42","author":"Goker-Alpan","year":"2005","journal-title":"J. Med. Genet."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2016.12.001_bb0380","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/gb-2011-12-s1-p26","article-title":"The mutation spectrum in Indian patients with Gaucher disease [abstract]","volume":"12","author":"Bisariya","year":"2011","journal-title":"Genome Biol."},{"issue":"5","key":"10.1016\/j.ymgme.2016.12.001_bb0385","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.ymgme.2016.12.001_bb0390","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/08035250500423804","article-title":"Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease","volume":"95","author":"Erikson","year":"2006","journal-title":"Acta Paediatr."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216303006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216303006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T01:26:40Z","timestamp":1536197200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216303006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":77,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1096719216303006"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.12.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}